Company > Strategy

Acacia Pharma aims to become a leading hospital pharmaceuticals business selling products directly to anesthesiologists and oncologists in the US. The key elements of this strategy are:

  • Gain US approval for BARHEMSYS® for the prophylaxis and treatment of PONV - approved February 2020
  • Gain US approval for BYFAVO™, a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less - approved July 2020
  • Directly commercialize BARHEMSYS® and BYFAVO™ in the US through our own sales and marketing infrastructure starting in 2H 2020
  • Establish strategic partnerships for the commercialization of BARHEMSYS® and APD403 outside the US with companies that have local expertise and commercial infrastructure, initially focusing on the major pharmaceutical markets
  • Leverage our US commercial infrastructure to sell APD403 for CINV to oncologists
  • Consider the further in-licensing or acquisition of complementary products or product candidates that can be commercialized effectively through our US organization